Multiple System Atrophy: Clinical Trials

5 trials for Multiple System Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 active not recruiting. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Active not recruiting 5

Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
YA-101, Placebo - Multiple System Atrophy
Phase 2Active not recruitingDasher Neuroscience Inc.752025-03-032026-08-19
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
TEV-56286, Placebo - Multiple System Atrophy
Phase 2Active not recruitingTeva Branded Pharmaceutical Products R&D LLC3492024-10-022026-11-05
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
ONO-2808, Placebo - Multiple System Atrophy (MSA)
Phase 2Active not recruitingOno Pharmaceutical Co., Ltd.922023-09-222026-10-06
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Autologous Mesenchymal Stem Cells, Placebo - Multiple System Atrophy
Phase 2Active not recruitingMayo Clinic712021-12-152026-06-12
A Study of Lu AF82422 in Participants With Multiple System Atrophy
Lu AF82422, Placebo - Multiple System Atrophy
Phase 2Active not recruitingH. Lundbeck A/S642021-11-162026-04-13

Narrower conditions

Neurodegenerative Diseases (1)  ·  Pure Autonomic Failure (1)

Broader conditions

Autonomic Nervous System Diseases (5)  ·  Basal Ganglia Diseases (5)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Movement Disorders (5)  ·  Nervous System Diseases (5)  ·  Primary Dysautonomias (5)  ·  Synucleinopathies (5)  ·  Neurodegenerative Diseases (4)

Interventions

3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (1)

Sponsors

Dasher Neuroscience Inc. (1)  ·  H. Lundbeck A/S (1)  ·  Mayo Clinic (1)  ·  Ono Pharmaceutical Co., Ltd. (1)  ·  Teva Branded Pharmaceutical Products R&D LLC (1)

Countries

United States (5)  ·  Japan (4)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Serbia (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Project Leader (1)  ·  Wolfgang Singer, MD (1)

Results publications

PMID 42044642

NIH funding

2023 (1)